PNC Financial Services Group
SPRO icon

PNC Financial Services Group’s Spero Therapeutics SPRO Stock Holding History

PNC Financial Services Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14
Closed – – 4038
2020
Q2 		$0 Buy
+14
New +$157 ﹤0.01% 4042
2020
Q1 		– Sell
-32,000
Closed -$308K – 4036
2019
Q4 		$308K Hold
32,000
– – ﹤0.01% 1791
2019
Q3 		$340K Hold
32,000
– – ﹤0.01% 1821
2019
Q2 		$368K Hold
32,000
– – ﹤0.01% 1801
2019
Q1 		$410K Buy
32,000
+16,200
+103% +$172K ﹤0.01% 1738
2018
Q4 		$98K Buy
15,800
+5,800
+58% +$47K ﹤0.01% 2472
2018
Q3 		$106K Hold
10,000
– – ﹤0.01% 2567
2018
Q2 		$146K Buy
+10,000
New +$128K ﹤0.01% 2386

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PNC Financial Services Group's SPRO Position: Q3 2020 in Review

PNC Financial Services Group sold out of Spero Therapeutics (SPRO) in Q3 2020, closing a stake of 14 shares.

PNC Financial Services Group first reported a position in SPRO in Q2 2018 and held it in 8 quarters. The position peaked at $410K in Q1 2019. 78 funds tracked by Wall St. Rank hold SPRO as of Q3 2020.

  • PNC Financial Services Group reported no remaining Spero Therapeutics position as of Q3 2020 after selling out during the quarter.
  • PNC Financial Services Group sold 14 Spero Therapeutics shares in Q3 2020.
  • PNC Financial Services Group first reported a position in Spero Therapeutics in Q2 2018 and held it in 8 quarters.
  • PNC Financial Services Group's Spero Therapeutics position peaked at $410K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2020.

Based on PNC Financial Services Group's 13F filing for Q3 2020, filed 6 Nov 2020.